Clive Bates is the director of Counterfactual Consulting and the former director of Action on Smoking and Health (U.K.). On this page we feature a selection of his contributions to Tobacco Reporter.
How can the science of tobacco and nicotine serve the public good?
Will the European Union enable or obstruct the market-based demise of the cigarette?
Officials should approach COP10 with clarity about their national goals and with tough questions about trade-offs, unintended consequences and evidence.
Read the work of Tobacco Reporter’s special contributor Clive Bates.
Clive Bates on how the tobacco industry can accelerate transformation
To see clearly into the decades ahead, we need to rethink nicotine.
Five types of innovation
What is bad science, and why is there so much of it?
The idea that e-cigarette flavors hook kids is simple, compelling and false.
Explaining the opposition to the industry’s diversification.
Innovation and creative destruction will render cigarettes obsolete—if we let it.
The availability of nicotine with minimal harm justifies a rethink of our approach to this drug.
Rules to reduce nicotine in cigarettes are back on the agenda.
What lessons should regulators learn from the United States?
The automatic criticism of everything associated with tobacco is not merely misguided; it has the potential to do real harm.
Prohibition and illicit trade
The two camps in tobacco control
Sustainability, strategy and survival in the tobacco market
The World Health Organization and tobacco policy: a seven-point reform agenda
Why public health campaigners remain so vehemently opposed to vapor products.
Our contributor Clive Bates challenges the governing idea of tobacco control
It is time to confront the fundamental confusion about the public health aims for tobacco and nicotine policy.
Smoking, nicotine and Covid-19: What is going on?
What does Brexit mean for tobacco and vaping?
In the vaping debate, falsehood flies and the truth comes limping after it
The absence of long-term studies does not justify stifling potentially less harmful nicotine products.
In debating the relative risks of nicotine products, one consideration trumps all others.
How to regulate reduced-risk products
Can there be an ethical tobacco company—and what would it do?
GTNF—where the tobacco industry goes to think